News >

Novel Approaches Seek to Enhance Efficacy of Osimertinib in EGFR+ NSCLC

Caroline Seymour
Published: Friday, Jun 14, 2019

Jeffrey M. Clarke, MD

Jeffrey M. Clarke, MD

Despite the sequential efficacy of some of the FDA-approved EGFR TKIs, frontline osimertinib (Tagrisso) confers the greatest progression-free survival (PFS) advantage for patients with EGFR-positive non–small cell lung cancer (NSCLC), explained Jeffrey M. Clarke, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication